RO5045337 (RG7112)

RO5045337 · Hoffmann-La Roche

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RO5045337 (RG7112), covering 2016-11-02 to 2016-11-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors [Phase 1]